甲基甲增加细胞周围的覆盖面,并减轻细胞周围的损伤,以提高动脉样硬化斑块的稳定性
Lei Zhang1, Yuan Li2, Wenqing Yang2
1College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250355, China.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|October 23, 2023
概括
甲基甲基 (PCAD) 增强动脉样硬化斑块的稳定性,通过增加细胞周围的覆盖面和功能. 这种天然的多能通过TGF-β1/TGFBR1/Smad2/3通路保护氧-LDL诱导的损伤.
科学领域:
- 心血管研究研究心血管研究
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 细胞功能障碍和损失是动脉样硬化斑块不稳定和破裂的关键驱动因素.
- 作为一种天然的多类化合物,Protocatechuic aldehyde (PCAD) 具有抗动脉样硬化特性,但其对细胞周围细胞的影响尚不清楚.
- 了解PCAD对细胞周围细胞招募,覆盖和功能的影响,对于开发新型治疗策略至关重要.
研究的目的:
- 研究PCAD对动脉样硬化细胞行为和功能的影响和潜在机制.
- 确定PCAD是否可以通过调节细胞周周覆盖和减轻细胞周损伤来改善动脉样硬化斑块的稳定性.
- 阐明PCAD对皮细胞的保护作用所涉及的特定信号通路.
主要方法:
- 动脉样硬化被诱导在非脂质蛋白E缺乏的小鼠中,食高脂肪饮食,随后接受PCAD治疗.
- 评估脂质水平,斑块表型,原沉积,巨细胞积累和细胞周围细胞覆盖率.
- 在实验室中评估了VEGF-A的产生,内新血管化和PCAD对ox-LDL诱导的周细胞功能障碍的影响.
- 研究了TGF-β1/TGFBR1/Smad2/3信号传递的作用,通过在人类微血管细胞中使用TGFBR1沉默来进行信号传递.
主要成果:
- 治疗PCAD显著降低了脂质水平,并防止了动脉样硬化进展,与罗斯瓦斯塔丁相当.
- 通过减少脂质含量和巨细胞透,PCAD的使用提高了斑块稳定性,同时增加了原沉积.
- PCAD治疗增加了细胞周围细胞覆盖率,减少了VEGF-A,并抑制了内新血管化.
- PCAD促进了细胞周细胞的增殖,粘附和迁移,缓解了ox-LDL诱导的功能障碍,并保持了毛细血管网络的稳定性.
- 通过TGF-β1/TGFBR1/Smad2/3信号通路,PCAD对皮细胞的保护作用得到了调解.
结论:
- PCAD有效地增加细胞周覆盖,并减轻ox-LDL诱导的细胞周损伤,从而改善动脉样硬化斑块的稳定性.
- 这种机制涉及TGF-β1/TGFBR1/Smad2/3信号通路的调节.
- 通过向细胞介导机制,PCAD代表了一种有前途的治疗药物,用于控制动脉样硬化.
相关概念视频
01:30Atherosclerosis I: Introduction
9
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
9
01:26Coronary Artery Disease II: Pathophysiology
12
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
12
01:26Atherosclerosis III: Management
11
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11
01:38Inflammation
53.7K
Overview
53.7K
01:27Coronary Artery Disease V: Interprofessional Care
9
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
9
01:27Peripheral Artery Disease III: Interprofessional Care
11
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
11